(function(){var loadHandler=window['sl_{033B8E9B-BD84-4FAD-91B7-AB568FDDDEE2}'];loadHandler&&loadHandler(17, '<div id="spr0_1345fdfd"><div id="spr1_1345fdfd" class="kern slide"><img id="img5_1345fdfd" src="data/img2.png" width="720px" height="1280px" alt="" style="left:0px;top:0px;"/><div id="spr3_1345fdfd" style="left:-0px;top:0.083px;"><div id="spr4_1345fdfd"><img id="img0_1345fdfd" src="data/img0.svg#svgView(preserveAspectRatio(none);viewBox(0 0 1080 1920))" width="720.047" height="1279.917" alt=""/></div></div><div id="spr5_1345fdfd" style="top:0.083px;"><div id="spr6_1345fdfd"><img id="img1_1345fdfd" src="data/img35.svg#svgView(preserveAspectRatio(none);viewBox(0 0 1080 1920))" width="720" height="1279.833" alt=""/></div></div><a id="hl0_1345fdfd" href="#" onclick="document.getElementById(\'coreSpr_4559708\').getCore().processTriggerEffect(this);document.getElementById(\'coreSpr_4559708\').getCore().gotoSlide(4, this);return false;" style="left:89.143px;top:130.213px;"><div id="svg0_1345fdfd" style="left:0px;top:0px;"><svg width="72" height="53" viewBox="0 0 72 53"><path fill="#ffffff" fill-opacity="0" d="M0,0 h71.689 v52.685 h-71.689 Z"/></svg></div></a><a id="hl1_1345fdfd" href="#" onclick="document.getElementById(\'coreSpr_4559708\').getCore().processTriggerEffect(this);document.getElementById(\'coreSpr_4559708\').getCore().gotoSlide(7, this);return false;" style="left:160.831px;top:130.213px;"><div id="svg1_1345fdfd" style="left:0px;top:0px;"><svg width="105" height="53" viewBox="0 0 105 53"><path fill="#ffffff" fill-opacity="0" d="M0,0 h104.104 v52.685 h-104.104 Z"/></svg></div></a><a id="hl2_1345fdfd" href="#" onclick="document.getElementById(\'coreSpr_4559708\').getCore().processTriggerEffect(this);document.getElementById(\'coreSpr_4559708\').getCore().gotoSlide(10, this);return false;" style="left:264.935px;top:130.213px;"><div id="svg2_1345fdfd" style="left:0px;top:0px;"><svg width="63" height="53" viewBox="0 0 63 53"><path fill="#ffffff" fill-opacity="0" d="M0,0 h62.532 v52.685 h-62.532 Z"/></svg></div></a><a id="hl3_1345fdfd" href="#" onclick="document.getElementById(\'coreSpr_4559708\').getCore().processTriggerEffect(this);document.getElementById(\'coreSpr_4559708\').getCore().gotoSlide(14, this);return false;" style="left:329.715px;top:130.213px;"><div id="svg3_1345fdfd" style="left:0px;top:0px;"><svg width="106" height="53" viewBox="0 0 106 53"><path fill="#ffffff" fill-opacity="0" d="M0,0 h105.351 v52.685 h-105.351 Z"/></svg></div></a><a id="hl4_1345fdfd" href="#" onclick="document.getElementById(\'coreSpr_4559708\').getCore().processTriggerEffect(this);document.getElementById(\'coreSpr_4559708\').getCore().gotoSlide(17, this);return false;" style="left:440.135px;top:130.213px;"><div id="svg4_1345fdfd" style="left:0px;top:0px;"><svg width="106" height="53" viewBox="0 0 106 53"><path fill="#ffffff" fill-opacity="0" d="M0,0 h105.351 v52.685 h-105.351 Z"/></svg></div></a><a id="hl5_1345fdfd" href="#" onclick="document.getElementById(\'coreSpr_4559708\').getCore().processTriggerEffect(this);document.getElementById(\'coreSpr_4559708\').getCore().gotoSlide(0, this);return false;" style="left:23.065px;top:130.213px;"><div id="svg5_1345fdfd" style="left:0px;top:0px;"><svg width="67" height="53" viewBox="0 0 67 53"><path fill="#ffffff" fill-opacity="0" d="M0,0 h66.078 v52.685 h-66.078 Z"/></svg></div></a></div><div id="spr2_1345fdfd" class="kern slide"><div id="svg6_1345fdfd" style="left:20.068px;top:325.586px;"><svg width="680" height="243" viewBox="-17.654 -17.654 680 243"><path fill="#ffffff" d="M0,0 A0,0 0 0,1 0,0 H626.792 A17.654,17.654 0 0,1 644.445,17.654 V207.469 A0,0 0 0,1 644.445,207.469 H17.654 A17.654,17.654 0 0,1 0,189.816 Z"/></svg></div><div id="svg8_1345fdfd" style="left:16.572px;top:529.659px;"><svg width="229" height="89" viewBox="-21.154 -21.154 229 89"><g fill="none"><path fill="#2069e7" transform="matrix(-1,0,0,1,207.678101,0)" d="M0,0 H186.524 A21.154,21.154 0 0,1 207.678,21.154 V66.931 H0 Z"/></g></svg></div><img id="img2_1345fdfd" src="data/img36.png" width="578.505" height="205.547" alt="" style="left:104.161px;top:345.753px;"/><div id="spr7_1345fdfd" style="left:104.161px;top:345.753px;"><div style="width:0px;"><span id="txt0_1345fdfd" class="nokern" data-width="198.661621" style="left:19.398px;top:22.756px;">Primary tumor size and extent</span></div><div style="width:0px;"><span id="txt1_1345fdfd" class="nokern relpos" dir="auto" style="left:19.413px;top:50.397px;">•</span> <span id="txt2_1345fdfd" class="nokern relpos" data-width="508.884247" style="left:29.396px;top:49.978px;">The changes in the definitions of Stages T1a and T1b may potentially lead to a</span></div><div style="width:0px;"><span id="txt3_1345fdfd" class="nokern" data-width="472.358398" style="left:34.531px;top:69.95px;">greater number of patients undergoing sentinel lymph node (SLN) biopsy</span></div><div style="width:0px;"><span id="txt4_1345fdfd" class="nokern relpos" dir="auto" style="left:19.413px;top:97.591px;">•</span> <span id="txt5_1345fdfd" class="nokern relpos" data-width="469.436920" style="left:29.396px;top:97.172px;">Patients with no ulceration and a Breslow thickness of 0.8–1.0 mm, who</span></div><div style="width:0px;"><span id="txt6_1345fdfd" class="nokern" data-width="497.391602" style="left:34.531px;top:114.77px;">were classified as T1a in the 7th edition of the AJCC Cancer Staging Manual,</span></div><div style="width:0px;"><span id="txt7_1345fdfd" class="nokern" data-width="446.687927" style="left:34.531px;top:132.367px;">have been reclassified as T1b in the 8th edition, to reflect their worse</span></div><div style="width:0px;"><span id="txt8_1345fdfd" class="nokern" data-width="494.047638" style="left:34.531px;top:149.965px;">melanoma-specific survival and increased risk of SLN metastasis compared</span></div><div style="width:0px;"><span id="txt9_1345fdfd" class="nokern" data-width="414.888031" style="left:34.531px;top:167.563px;">to patients with non-ulcerated melanomas &lt;0.8 mm (Stage T1a)</span></div></div><div id="spr8_1345fdfd" style="left:37.722px;top:414.537px;"><div style="width:0px;"><span id="txt10_1345fdfd" style="left:18.97px;top:-0.008px;">T</span></div></div><div id="spr9_1345fdfd" style="left:36.818px;top:1145.453px;"><div style="width:0px;"><span id="txt11_1345fdfd" class="nokern" data-width="355.505798" style="top:-14.363px;">AJCC, American Joint Committee on Cancer; CNS, central nervous system. </span></div><div style="width:0px;"><span id="txt12_1345fdfd" class="nokern relpos" data-width="54.779327" style="top:-0.179px;">Reference: </span> <span id="txt13_1345fdfd" class="nokern relpos" data-width="156.026566" style="left:-0.007px;top:-0.179px;">1. Keung EZ and Gershenwald JE</span> <span id="txt14_1345fdfd" class="nokern relpos" data-width="134.413132" style="left:-0.013px;top:-0.179px;">. Expert Rev Anticancer Ther</span> <span id="txt15_1345fdfd" class="nokern relpos" data-width="91.956779" style="left:-0.02px;top:-0.179px;">. 2018;18:775–784.</span></div><div style="width:0px;"><span id="txt16_1345fdfd" class="nokern" data-width="163.358948" style="top:13.248px;">US-UNB-EM-24-03-0020 April 2024</span></div></div><img id="img3_1345fdfd" src="data/img37.png" width="633.972" height="319.507" alt="" style="left:49.764px;top:570.584px;"/><div id="svg12_1345fdfd" style="left:15.669px;top:868.312px;"><svg width="340" height="89" viewBox="-21.154 -21.154 340 89"><g fill="none"><path fill="#2069e7" transform="matrix(-1,0,0,1,318.236237,0)" d="M0,0 H297.082 A21.154,21.154 0 0,1 318.236,21.154 V66.931 H0 Z"/></g></svg></div><div id="spr10_1345fdfd" style="left:104.661px;top:571.535px;"><div style="width:0px;"><span id="txt17_1345fdfd" class="nokern" data-width="319.502655" style="left:18.898px;top:22.803px;">Number of regional tumor-involved lymph nodes</span></div><div style="width:0px;"><span id="txt18_1345fdfd" class="nokern relpos" dir="auto" style="left:18.913px;top:50.444px;">•</span> <span id="txt19_1345fdfd" class="nokern relpos" data-width="481.194489" style="left:28.896px;top:50.025px;">Differences in prognosis between the 7th and 8th edition staging systems,</span></div><div style="width:0px;"><span id="txt20_1345fdfd" class="nokern" data-width="495.651581" style="left:34.031px;top:67.623px;">particularly of patients with Stage IIIA and Stage IIIB disease, have important</span></div><div style="width:0px;"><span id="txt21_1345fdfd" class="nokern" data-width="471.062347" style="left:34.031px;top:85.22px;">implications for clinical decisions, patient counseling, and risk-stratifying</span></div><div style="width:0px;"><span id="txt22_1345fdfd" class="nokern" data-width="354.818359" style="left:34.031px;top:105.192px;">patients for consideration of possible adjuvant therapy</span></div><div style="width:0px;"><span id="txt23_1345fdfd" class="nokern relpos" dir="auto" style="left:18.913px;top:132.833px;">•</span> <span id="txt24_1345fdfd" class="nokern relpos" data-width="471.291473" style="left:28.896px;top:132.414px;">Currently available adjuvant systemic therapies for melanoma have been</span></div><div style="width:0px;"><span id="txt25_1345fdfd" class="nokern" data-width="468.083557" style="left:34.031px;top:150.012px;">evaluated in patients with Stage IIB–IV disease based on previous AJCC</span></div><div style="width:0px;"><span id="txt26_1345fdfd" class="nokern" data-width="483.564636" style="left:34.031px;top:167.61px;">editions; however, some of these patients are categorized differently in the</span></div><div style="width:0px;"><span id="txt27_1345fdfd" class="nokern" data-width="72.686501" style="left:34.031px;top:187.581px;">8th edition:</span></div><div style="width:0px;"><span id="txt28_1345fdfd" class="nokern relpos" dir="auto" style="left:47.764px;top:215.222px;">•</span> <span id="txt29_1345fdfd" class="nokern relpos" data-width="443.057526" style="left:55.963px;top:214.803px;">Patients with Stage IIIA disease have a better prognosis under AJCC</span></div><div style="width:0px;"><span id="txt30_1345fdfd" class="nokern" data-width="469.243561" style="left:61.098px;top:234.775px;">8th edition, as patients with worse prognosis are included in later stages</span></div><div style="width:0px;"><span id="txt31_1345fdfd" class="nokern relpos" dir="auto" style="left:47.764px;top:262.416px;">•</span> <span id="txt32_1345fdfd" class="nokern relpos" data-width="432.202179" style="left:55.963px;top:261.997px;">Patients with Stage IIID were previously included in other groups in</span></div><div style="width:0px;"><span id="txt33_1345fdfd" class="nokern" data-width="99.158958" style="left:61.098px;top:279.595px;">earlier versions</span></div></div><div id="spr11_1345fdfd" style="left:37.721px;top:695.846px;"><div style="width:0px;"><span id="txt34_1345fdfd" style="left:17.137px;top:-0.008px;">N</span></div></div><img id="img4_1345fdfd" src="data/img38.png" width="633.972" height="122.686" alt="" style="left:48.861px;top:909.827px;"/><div id="svg15_1345fdfd" style="left:16.572px;top:1010.7px;"><svg width="143" height="89" viewBox="-21.154 -21.154 143 89"><g fill="none"><path fill="#2069e7" transform="matrix(-1,0,0,1,121.369125,0)" d="M0,0 H100.215 A21.154,21.154 0 0,1 121.369,21.154 V66.931 H0 Z"/></g></svg></div><div id="spr12_1345fdfd" style="left:104.661px;top:910.493px;"><div style="width:0px;"><span id="txt35_1345fdfd" class="nokern" data-width="369.311279" style="left:18.898px;top:21.267px;">Whether and where the primary tumor has metastasized</span></div><div style="width:0px;"><span id="txt36_1345fdfd" class="nokern relpos" dir="auto" style="left:18.913px;top:48.908px;">•</span> <span id="txt37_1345fdfd" class="nokern relpos" data-width="470.575439" style="left:28.896px;top:48.489px;">The addition of the new Stage M1d designation to describe patients with</span></div><div style="width:0px;"><span id="txt38_1345fdfd" class="nokern" data-width="501.866943" style="left:34.031px;top:66.087px;">distant metastasis to the CNS with or without other distant sites of disease is</span></div><div style="width:0px;"><span id="txt39_1345fdfd" class="nokern" data-width="370.815002" style="left:34.031px;top:83.684px;">intended to reflect the poorer prognosis of these patients</span></div></div><div id="spr13_1345fdfd" style="left:37.721px;top:939.165px;"><div style="width:0px;"><span id="txt40_1345fdfd" style="left:13.22px;top:-0.008px;">M</span></div></div><div id="spr14_1345fdfd" style="left:37.721px;top:211.374px;"><div style="width:0px;"><span id="txt41_1345fdfd" class="relpos" data-width="399.804718" style="top:-2.97px;">Impact of Melanoma Staging Updates</span> <span id="txt42_1345fdfd" class="relpos" style="left:-0.007px;top:-2.523px;">1</span></div></div><div id="spr15_1345fdfd" style="left:37.721px;top:268.443px;"><div style="width:0px;"><span id="txt43_1345fdfd" data-width="512.808228" style="top:-0.002px;">Melanoma staging will continue to evolve as new prognostic factors and</span></div><div style="width:0px;"><span id="txt44_1345fdfd" data-width="465.829987" style="top:19.195px;">evidence-based approaches are developed, refined, and validated.</span></div></div><a id="hl6_1345fdfd" href="#" onclick="document.getElementById(\'coreSpr_4559708\').getCore().processTriggerEffect(this);document.getElementById(\'coreSpr_4559708\').getCore().gotoSlide(14, this);return false;" style="left:277.271px;top:1204.339px;"><div id="svg16_1345fdfd" style="left:0px;top:0px;"><svg width="165" height="51" viewBox="0 0 165 51"><path fill="#ffffff" fill-opacity="0" d="M0,0 h164.443 v50.127 h-164.443 Z"/></svg></div></a></div></div>', '{"s":[]}');})();